“We continue to expect core revenue growth of approximately 3%, which assumes better performance in our bioprocessing business will be offset by slightly more modest expectations for life sciences.”

In context

“st efficiently allocate resources, Cepheid's point of care molecular testing is proving increasingly valuable, offering greater efficiency through fewer total tests, higher rates of correct treatment and ultimately lower treatment costs compared to other testing strategies. So now let's frame how we're thinking about the second quarter and the full year 2025. We expect end market demand remains relatively consistent with the first quarter for the remainder of 2025. Regarding tariffs, based on what is currently implemented, we believe we can largely offset the impact from these tariffs through a combination of supply chain adjustments, surcharges, manufacturing footprint changes and other cost actions. Now for the full year 2025, there is essentially no change to our previous expectations. We continue to expect core revenue growth of approximately 3%, which assumes better performance in our bioprocessing business will be offset by slightly more modest expectations for life sciences. Additionally, we're initiating full year adjusted diluted EPS guidance in the range of $7.60 to $7.75. Given the current environment, we believe providing adjusted EPS guidance offers the best anchor point for assessing business performance and will provide better clarity for our investors. In the second quarter, we expect core revenue to grow in the low-single digit percent range. And additionally, we expect a second quarter adjusted operating profit margin of approximately 25.5%, reflecting normal seasonality in Cepheid's respiratory business and continued productivity investments. So to wrap it up, we're confident in our positioning in what could be choppy waters and we're leveraging the Danaher Business System to ensure we navigate this environment from a position of strength. DBS is”